Takeda Pharmaceutical Company Limited http://www.takeda.com All Updates Takeda Pharmaceutical Company Limited http://www.takeda.com http://www.takeda.com/favicon.ico icon Takeda Announces Appointment of New Senior Leadershiphttp://www.takeda.com/news/2013/20130521_5786.htmlOsaka, Japan, May 21, 2013--- Takeda Pharmaceutical Company Limited today announced new appointment of senior leadership. The details are as follows;2013-05-21T11:00+09:0026_5786@http://www.takeda.com Takeda and Lundbeck Present Results from Pivotal Phase 3 Clinical Trials with Vortioxetine, an Investigational Compound for Major Depressive Disorderhttp://www.takeda.com/news/2013/20130520_5782.htmlSan Francisco, California – May 18, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck)  today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of dep2013-05-20T08:00+09:0026_5782@http://www.takeda.com Fasiglifam (TAK-875), a Novel GPR40 Agonist Reduces HbA1c in a 24-Week Clinical Study - Phase III Study Results Presented at the 56th Annual Meeting of the Japan Diabetes Societyhttp://www.takeda.com/news/2013/20130516_5780.htmlOsaka, Japan, May 16, 2013 --- Takeda Pharmaceutical Company Limited ("Takeda") announced today the results of a Phase III clinical trial (CCT-003) of fasiglifam (Development code:TAK-875) for the treatment of type 2 diabetes presented at the 56th Annual Meeting of the Japan Diabetes Socie2013-05-16T15:00+09:0026_5780@http://www.takeda.com Takeda Pharmaceutical Company Limited Announces Mid-Range Growth Strategy Starting from the Fiscal Year 2013 (Ending March 31, 2014)http://www.takeda.com/news/2013/20130509_5767.htmlOsaka, Japan, May 9, 2013 --- Takeda Pharmaceutical Company Limited (“Takeda”, “the Company”) today announced its “Vision 2020,” and commenced its Mid-Range Growth Strategy starting from fiscal 2013 that aims to realize where the company as2013-05-09T15:00+09:0026_5767@http://www.takeda.com Takeda Pharmaceutical Company Limited Announces Financial Results for the Fiscal Year Ended March 31, 2013 and Forecasts for the Fiscal Year Ending March 31, 2014http://www.takeda.com/news/2013/20130509_5766.htmlOsaka, Japan, May 9, 2013 --- Takeda Pharmaceutical Company Limited (“Takeda”, “the Company”) announced today the consolidated financial results for the fiscal year ended March 31, 2013, and forecasts of consolidated results for the fiscal year ending March 312013-05-09T15:00+09:0026_5766@http://www.takeda.com Takeda Voluntarily Adopts International Financial Reporting Standards (IFRS)http://www.takeda.com/news/2013/20130509_5765.htmlOsaka, Japan, May 9, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) announced that it has resolved at a meeting of the Board of Directors held today that, as of the fiscal year ending March 31, 2014 (fiscal year 2013, “FY2013”), i2013-05-09T15:00+09:0026_5765@http://www.takeda.com Takeda Announces the Revision of Consolidated Financial Forecastsfor Fiscal 2013http://www.takeda.com/news/2013/20130509_5764.htmlOsaka, Japan, May 9, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”, “the Company”) announced today a revision to the consolidated financial forecasts for fiscal year ending March 31, 2014, (“fiscal 2013”) that were previo2013-05-09T15:00+09:0026_5764@http://www.takeda.com Takeda Appoints New President for Millennium: The Takeda Oncology Companyhttp://www.takeda.com/news/2013/20130509_5763.htmlOsaka, Japan, May 9, 2013 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced today that effective May 9, 2013, Anna Protopapas, currently Corporate Officer, Executive Vice President and Global Business Development Head, Takeda Pharmaceuticals International, Inc.* loca2013-05-09T15:00+09:0026_5763@http://www.takeda.com Takeda to Acquire Inviragen, Inc.http://www.takeda.com/news/2013/20130508_5757.htmlOsaka, Japan, May 8, 2013, Deerfield, IL and Fort Collins, CO, U.S.A., May 7, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) and Inviragen, Inc. (“Inviragen”) jointly announced today that Takeda, its wholly owned subsidiary Takeda America Ho2013-05-08T08:00+09:0026_5757@http://www.takeda.com Takeda Announces Appointment of New Senior Leadershiphttp://www.takeda.com/news/2013/20130425_5755.htmlOsaka, Japan, April 25, 2013 --- Takeda Pharmaceutical Company Limited today announced new appointment of senior leadership. The details are as follows;2013-04-25T16:00+09:0026_5755@http://www.takeda.com